MTAP deficiency creates an exploitable target for antifolate therapy in 9p21-loss cancers.
Alhalabi O, Chen J, Zhang Y, Lu Y, Wang Q, Ramachandran S, Tidwell RS, Han G, Yan X, Meng J, Wang R, Hoang AG, Wang WL, Song J, Lopez L, Andreev-Drakhlin A, Siefker-Radtke A, Zhang X, Benedict WF, Shah AY, Wang J, Msaouel P, Zhang M, Guo CC, Czerniak B, Behrens C, Soto L, Papadimitrakopoulou V, Lewis J, Rinsurongkawong W, Rinsurongkawong V, Lee J, Roth J, Swisher S, Wistuba I, Heymach J, Wang J, Campbell MT, Efstathiou E, Titus M, Logothetis CJ, Ho TH, Zhang J, Wang L, Gao J.
Alhalabi O, et al. Among authors: lu y.
Nat Commun. 2022 Apr 4;13(1):1797. doi: 10.1038/s41467-022-29397-z.
Nat Commun. 2022.
PMID: 35379845
Free PMC article.
Clinical Trial.